NEWS
Mabqi is proud to co-author the scientific article « Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings» published in mAbs, November 2024.
The research project led by IOME Bio focused on developing antibodies targeting Repulsive Guidance Molecule b (RGMb), a novel...
Mabqi will be attending BIO EUROPE 2024
Mabqi will be attending the Festival of Biologics from October 15th to October 17th 2024 in Basel, Switzerland.
Mabqi will be attending the FOB 2024
Mabqi will be attending the Festival of Biologics from October 15th to October 17th 2024 in Basel, Switzerland.
Mabqi will be attending at the Convention BIO US 2024
Mabqi will be attending the Convention BIO US innovation organization from June 3rd to June 6th at #SanDiego, #California...
Mabqi contributed to the article « Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis » published in the journal Nature Communications on August 31, 2023.
Mabqi is proud to have contributed to the article "Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic...
Mabqi moved!
More labs and office space for delivering outstanding antibodies in Montpellier! Our new address is: CAP SIGMA - ZAC Euromédecine II...